Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Swathi Ramakrishnan

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Oncotarget|January 22, 2015
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancerJason S Kirk, Kevin Schaarschuch, Zafardjan Dalimov, et al.
Cancer Research Communications|October 24, 2022
STAG2 expression is associated with adverse survival outcomes and regulates cell phenotype in muscle-invasive bladder cancerSarah Athans, Nithya Krishnan, Swathi Ramakrishnan, et al.
Genome Medicine|April 2, 2024
Race-specific coregulatory and transcriptomic profiles associated with DNA methylation and androgen receptor in prostate cancerSwathi Ramakrishnan, Eduardo Cortes-Gomez, Sarah R Athans, et al.
The Prostate|May 12, 2019
Association among plasma 1,25(OH)<sub>2</sub> D, ratio of 1,25(OH)<sub>2</sub> D to 25(OH)D, and prostate cancer aggressivenessSwathi Ramakrishnan, Susan E Steck, Lenore Arab, et al.
BMC Cancer|August 11, 2016
HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinomaSwathi Ramakrishnan, ShengYu Ku, Eric Ciamporcero, et al.
Cell Death and Differentiation|January 30, 2019
Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancerSwathi Ramakrishnan, Victoria Granger, Monika Rak, et al.
Cell Cycle (Georgetown, Tex.)|July 19, 2019
TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC)Brittany Bunch, Nithya Krishnan, Rebecca D Greenspan, et al.
Molecular Cancer Therapeutics|October 5, 2019
Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell CarcinomaMay Elbanna, Ashley R Orillion, Nur P Damayanti, et al.
American Journal of Clinical and Experimental Urology|January 7, 2022
Patient derived models of bladder cancer enrich the signal of the tumor cell transcriptome facilitating the analysis of the tumor cell compartmentMichalis Mastri, Swathi Ramakrishnan, Shruti D Shah, et al.
Cancer Immunology Research|November 6, 2014
Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine modelsLi Shen, Anette Sundstedt, Michael Ciesielski, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Oncotarget|January 22, 2015
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancerJason S Kirk, Kevin Schaarschuch, Zafardjan Dalimov, et al.
Cancer Research Communications|October 24, 2022
STAG2 expression is associated with adverse survival outcomes and regulates cell phenotype in muscle-invasive bladder cancerSarah Athans, Nithya Krishnan, Swathi Ramakrishnan, et al.
Genome Medicine|April 2, 2024
Race-specific coregulatory and transcriptomic profiles associated with DNA methylation and androgen receptor in prostate cancerSwathi Ramakrishnan, Eduardo Cortes-Gomez, Sarah R Athans, et al.
The Prostate|May 12, 2019
Association among plasma 1,25(OH)<sub>2</sub> D, ratio of 1,25(OH)<sub>2</sub> D to 25(OH)D, and prostate cancer aggressivenessSwathi Ramakrishnan, Susan E Steck, Lenore Arab, et al.
BMC Cancer|August 11, 2016
HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinomaSwathi Ramakrishnan, ShengYu Ku, Eric Ciamporcero, et al.
Cell Death and Differentiation|January 30, 2019
Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancerSwathi Ramakrishnan, Victoria Granger, Monika Rak, et al.
Cell Cycle (Georgetown, Tex.)|July 19, 2019
TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC)Brittany Bunch, Nithya Krishnan, Rebecca D Greenspan, et al.
Molecular Cancer Therapeutics|October 5, 2019
Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell CarcinomaMay Elbanna, Ashley R Orillion, Nur P Damayanti, et al.
American Journal of Clinical and Experimental Urology|January 7, 2022
Patient derived models of bladder cancer enrich the signal of the tumor cell transcriptome facilitating the analysis of the tumor cell compartmentMichalis Mastri, Swathi Ramakrishnan, Shruti D Shah, et al.
Cancer Immunology Research|November 6, 2014
Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine modelsLi Shen, Anette Sundstedt, Michael Ciesielski, et al.
Pageof 3